Drugs / MUFEMILAST
MUFEMILAST
Trials 17
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT06610890 | Dec 2024 → Jan 2025 | psoriasis | Ganzhou Hemay Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06380153 | May 2024 → Apr 2025 | psoriasis | Ganzhou Hemay Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06376474 | Apr 2024 → Dec 2025 overdue | psoriasis | Ganzhou Hemay Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT05941247 | Jul → Aug 2023 | — | Ganzhou Hemay Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT05468645 | Jul → Sep 2022 | — | Ganzhou Hemay Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT04837235 | Apr → Aug 2021 | psoriasis | Tianjin Hemay Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT03577626 | Oct → Nov 2018 | psoriasis | Tianjin Hemay Bio-Tech Co., Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT03570346 | Jul → Oct 2018 | psoriasis | Tianjin Hemay Bio-Tech Co., Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT03007810 | Dec 2016 → Jun 2018 | psoriasis | Tianjin Hemay Bio-Tech Co., Ltd | Completed | No outcome recorded |
| Phase 25 trials · 1 met primary | ||||||
| Phase 2 | NCT07314242 | Jan 2026 → Dec 2027 expected | chronic obstructive pulmonary disease | Ganzhou Hemay Pharmaceutical Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05769946 | Nov 2022 → Jan 2024 | atopic eczema | Ganzhou Hemay Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 2 | NCT05486104 | Nov 2022 → Dec 2026 expected | ulcerative colitis | Ganzhou Hemay Pharmaceutical Co., Ltd | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04609397 | Nov 2020 → Apr 2022 | Behcet disease | Tianjin Hemay Pharmaceutical Co., Ltd | Terminated | Met primary |
| Phase 2 | NCT04102241 | May 2019 → Oct 2020 | psoriasis | Tianjin Hemay Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07650942 | Jun 2026 → May 2028 expected | ulcerative colitis | Ganzhou Hemay Pharmaceutical Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06145893 | Nov 2023 → May 2026 overdue | Behcet disease | Ganzhou Hemay Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
| Phase 3 | NCT04839328 | Jan → Oct 2022 | psoriasis | Tianjin Hemay Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT06908642 Comparator | Dec 2024 → Jun 2025 | chronic obstructive pulmonary disease | Anhui Hemay Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 2 | NCT05407246 Comparator | Aug 2022 → Aug 2023 | ankylosing spondylitis | Tianjin Hemay Pharmaceutical Co., Ltd | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MUFEMILAST | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095240 ↗ |
| Known as | [14C]Hemay005 | “In Vivo Mass Balance Study of [14C]Hemay005” NCT05468645 ↗ |
| Known as | Hemay005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05769946 ↗ |
| Known as | Hemay005 tablet | “Hemay005 tablet” NCT04839328 ↗ |
| Action | Inhibit | “Hemay005 is a novel phosphodiesterase type 4(PDE4) inhibitor being developed for the treatment of psoriasis.” NCT03570346 ↗ |
| Modality | Small molecule | “Hemay005 is a small molecule PDE4 inhibitor.” NCT04102241 ↗ |
| Route | Oral | “Subjects will be randomized into 6 cohorts(10mg, 20mg, 40mg, 80mg, 120mg, 180mg) orally single dose” NCT03007810 ↗ |